The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
Alex PozdnyakovRoshini KulanthaiveluGlenn BaumanClaudia OrtegaPatrick Veit-HaibachUr MetserPublished in: Prostate cancer and prostatic diseases (2022)
In conclusion, PSMA PET is positive in more than 2/3 of men with BCR and impacts patient management in more than half of the men. BRFS after PET-directed management is 60% at a median of 20 months after salvage therapy, and complete biochemical response may be achieved in up to a quarter of men.